On this week’s Biotech Hangout, hosts Daphne Zohar, Mike Yee, Otello Stampacchia, Brad Loncar and Bruce Booth discuss the latest in the biopharma industry including public offerings, deals and financings, data and more. The group dives into the slowdowns in private financings, whether or not the IPO window should be open by now, and the Akero and Coherus follow-on offerings. There is a debate as to whether the news that the FTC is suing to block Amgen from acquiring Horizon Therapeutics has positive or negative effects on SMID cap biotechs. The group also discusses the FTC’s widening probe into PBMs specialty drug pricing. Additionally, data from Viking Therapeutics, X4 Pharmaceuticals, and PTC Therapeutics is discussed. Other topics include Pfizer debt offering, Former Immunomedics CFO pleads guilty to securities fraud, Billy Dunn joining the board of Prothena and Paul Stoffels joining Galapagos. *This episode aired on May 19, 2023*
